1. Home
  2. PHVS vs SHCO Comparison

PHVS vs SHCO Comparison

Compare PHVS & SHCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PHVS
  • SHCO
  • Stock Information
  • Founded
  • PHVS 2015
  • SHCO 1995
  • Country
  • PHVS Switzerland
  • SHCO United Kingdom
  • Employees
  • PHVS N/A
  • SHCO N/A
  • Industry
  • PHVS Biotechnology: Pharmaceutical Preparations
  • SHCO Hotels/Resorts
  • Sector
  • PHVS Health Care
  • SHCO Consumer Discretionary
  • Exchange
  • PHVS Nasdaq
  • SHCO Nasdaq
  • Market Cap
  • PHVS 980.9M
  • SHCO 1.0B
  • IPO Year
  • PHVS 2021
  • SHCO 2021
  • Fundamental
  • Price
  • PHVS $22.32
  • SHCO $7.25
  • Analyst Decision
  • PHVS Buy
  • SHCO Buy
  • Analyst Count
  • PHVS 6
  • SHCO 2
  • Target Price
  • PHVS $37.17
  • SHCO $7.25
  • AVG Volume (30 Days)
  • PHVS 33.8K
  • SHCO 279.8K
  • Earning Date
  • PHVS 08-13-2025
  • SHCO 08-08-2025
  • Dividend Yield
  • PHVS N/A
  • SHCO N/A
  • EPS Growth
  • PHVS N/A
  • SHCO N/A
  • EPS
  • PHVS N/A
  • SHCO N/A
  • Revenue
  • PHVS N/A
  • SHCO $1,224,734,000.00
  • Revenue This Year
  • PHVS N/A
  • SHCO $8.99
  • Revenue Next Year
  • PHVS N/A
  • SHCO $6.02
  • P/E Ratio
  • PHVS N/A
  • SHCO N/A
  • Revenue Growth
  • PHVS N/A
  • SHCO 8.21
  • 52 Week Low
  • PHVS $11.51
  • SHCO $4.43
  • 52 Week High
  • PHVS $25.76
  • SHCO $8.47
  • Technical
  • Relative Strength Index (RSI)
  • PHVS 73.31
  • SHCO 54.58
  • Support Level
  • PHVS $17.63
  • SHCO $7.41
  • Resistance Level
  • PHVS $19.00
  • SHCO $7.71
  • Average True Range (ATR)
  • PHVS 1.20
  • SHCO 0.27
  • MACD
  • PHVS 0.35
  • SHCO -0.03
  • Stochastic Oscillator
  • PHVS 92.15
  • SHCO 47.17

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

About SHCO Soho House & Co Inc.

Soho House & Co Inc is a membership platform of physical and digital spaces that connects a vibrant, diverse group of members from across the world. The members use the platform to work, socialize, connect, create, and flourish all over the world. It offers lease agreements for Houses, hotels, restaurants, studios, spas, and other properties. The company's reportable segments are: United Kingdom; The Americas; and Europe and Rest of the world. The majority of its revenue is generated from the Americas segment, which encompasses its operating units in the Americas, including Soho Houses, stand-alone U.S. restaurants, Soho Friends, and the management fees under a hotel management contract for the operation of The Ned London.

Share on Social Networks: